VIR BIOTECHNOLOGY, INC. (VIR) News
Filter VIR News Items
VIR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
VIR News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest VIR News From Around the Web
Below are the latest news stories about VIR BIOTECHNOLOGY INC that investors may wish to consider to help them evaluate VIR as an investment opportunity.
Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's WhyOn Wednesday, Vir Biotechnology, Inc. (NASDAQ:VIR) presented initial Phase 1 data from two of its dual-masked T-cell engagers (TCEs): VIR-5818, which targets a variety of HER2-expressing solid tumors, and VIR-5500, which targets PSMA in metastatic castration-resistant prostate cancer (mCRPC). Data show encouraging preliminary safety and efficacy profiles with no dose-limiting cytokine release syndrome, maximum tolerated dose not yet reached as dose escalation continues, and early clinical respon |
VIR Stock Up on Early Safety & Efficacy Data on Two Cancer CandidatesVir Biotechnology posts encouraging initial data from phase I studies evaluating VIR-5818 and VIR-5500 in heavily pretreated patients with various solid tumors. |
Vir Biotechnology Reports Promising Trial Results for Cancer TherapiesVir Biotechnology ( (VIR) ) has issued an update. Vir Biotechnology announced promising Phase 1 trial results for its dual-masked T-cell engagers, VIR-5818 and VIR-5500, targeting HER2-expressing solid tumors and PSMA in metastatic castration-resistant prostate cancer respectively. The data showed compelling early clinical responses and a favorable safety profile, with no dose-limiting toxicities and no severe cytokine release syndrome observed. The findings support the potential of Vir’s PRO-XT |
Vir Biotechnology Catapults 58% On Promising Results In Cancer TreatmentVir Biotechnology announced promising results Wednesday for a pair of cancer treatments, and Vir stock catapulted by double digits. |
Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPCSAN FRANCISCO, January 08, 2025--Vir Biotechnology, Inc. (Nasdaq: VIR) today is presenting initial Phase 1 data from two of its dual-masked T-cell engagers (TCEs): VIR-5818, targeting a variety of HER2-expressing solid tumors; and VIR-5500, targeting PSMA in metastatic castration-resistant prostate cancer (mCRPC). Data show encouraging preliminary safety and efficacy profiles with no dose-limiting cytokine release syndrome (CRS), maximum tolerated dose (MTD) not yet reached as dose escalation co |
Vir Biotechnology price target lowered to $14 from $15 at BofABofA lowered the firm’s price target on Vir Biotechnology (VIR) to $14 from $15 and keeps a Neutral rating on the shares. While political and rate uncertainty continues to be an overhang, the firm views the health of the Biopharma sector as “markedly improved from 2022 lows.” For stocks in its coverage, the firm continues to like late-stage clinical or early launch stories, although it sees Phase 1 clinical programs with derisking data and near-term catalysts as “increasingly areas of investor f |
Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceSAN FRANCISCO, December 18, 2024--Vir Biotechnology Inc. (NASDAQ: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, at 4:30 p.m. PT in San Francisco, California. |
Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis DeltaSAN FRANCISCO, December 12, 2024--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that tobevibart and elebsiran have received U.S. Food and Drug Administration (FDA) Breakthrough Therapy designation and European Medicines Agency (EMA) Priority Medicines (PRIME) designation for the treatment of chronic hepatitis delta (CHD). The designations are supported by compelling positive safety and efficacy data from the Phase 2 SOLSTICE trial, from which the Company recently presented new data at AA |
Janux Catapults 49% On 'Unprecedented' Results In Prostate Cancer; Vir Goes For A RideShares of Janux Therapeutics skyrocketed Tuesday on "unprecedented" results for an experimental prostate cancer treatment. |
Will Vir Biotechnology (NASDAQ:VIR) Spend Its Cash Wisely?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining... |